Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00454649 · ClinicalTrials.gov registry record · Phase 1
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
A Phase 1 study of Neoplasms, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 102
- Enrollment target
- 13
- Study locations
NCT00454649 is a Phase 1 study of Neoplasms that has completed, run by Pfizer. The registered enrollment target is 102 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (94% lower). The trial reports 13 study locations across 9 states.
The verdict
NCT00454649, a Phase 1 study of Neoplasms, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 102 participants
- Enrollment target
- 13
- Study locations
Study Summary
To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.
Conditions Studied
Interventions
- DRUG Axitinib + Paclitaxel + Carboplatin (Cohort 1)
- DRUG Axitinib + Paclitaxel + Carboplatin (Cohort 2)
- DRUG Axitinib + Paclitaxel + Carboplatin (Cohort 3)
- DRUG Axitinib + Paclitaxel (Cohort 4)
- DRUG Axitinib + Docetaxel + Carboplatin (Cohort 4a)
Study Locations (13)
Illinois
- Pfizer Investigational Site - Harvey
- Pfizer Investigational Site - Harvey
- Pfizer Investigational Site - Tinley Park
Georgia
- Pfizer Investigational Site - Augusta
- Pfizer Investigational Site - Augusta
Indiana
- Pfizer Investigational Site - Hobart
- Pfizer Investigational Site - Munster
Pennsylvania
- Pfizer Investigational Site - Philadelphia
Texas
- Pfizer Investigational Site - Houston
Washington
- Pfizer Investigational Site - Kennewick
Other
- Pfizer Investigational Site - Warsaw
Barcelona
- Pfizer Investigational Site - Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2005-12 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00454649
The ClinicalTrials.gov registry entry for NCT00454649 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (94% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Axitinib + Paclitaxel + Carboplatin (Cohort 1) is the first listed.
NCT00454649 reports 13 study locations spanning 9 distinct geographic areas - top geographies include Illinois, Georgia, Indiana.
Frequently Asked Questions
What is clinical trial NCT00454649 about?
NCT00454649 is a clinical study titled "Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor". To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.
What is the current status of trial NCT00454649?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2005-12. Estimated completion is 2011-04.
What conditions does trial NCT00454649 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT00454649?
The interventions under investigation include: Axitinib + Paclitaxel + Carboplatin (Cohort 1) (DRUG), Axitinib + Paclitaxel + Carboplatin (Cohort 2) (DRUG), Axitinib + Paclitaxel + Carboplatin (Cohort 3) (DRUG), Axitinib + Paclitaxel (Cohort 4) (DRUG), Axitinib + Docetaxel + Carboplatin (Cohort 4a) (DRUG).
Who is sponsoring clinical trial NCT00454649?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00454649 being conducted?
This trial has 13 study locations across Georgia, Illinois, Indiana, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.